Breast Cancer
Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at least two prior chemotherapy regimens (IMMU-132-09)
- Details
ClinicalTrials.gov ID:
NCT03901339
Diagnosis Type:
NA
USOR Number:
- Address
1760 E. Ken Pratt Blvd. Suite 302
Longmont, CO 80504
P: (303) 684-1900